BiomX Inc. (PHGE)

NYSEAMERICAN: PHGE · IEX Real-Time Price · USD
0.322
+0.002 (0.50%)
Mar 30, 2023, 10:17 AM EDT - Market open
0.5%
Market Cap 11.56M
Revenue (ttm) n/a
Net Income (ttm) -32.89M
Shares Out 35.96M
EPS (ttm) -1.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,841
Open 0.302
Previous Close 0.320
Day's Range 0.302 - 0.322
52-Week Range 0.132 - 2.140
Beta 1.35
Analysts Buy
Price Target 8.16 (+2,437.31%)
Earnings Date May 9, 2023

About PHGE

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 103
Stock Exchange NYSEAMERICAN
Ticker Symbol PHGE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for PHGE stock is "Buy." The 12-month stock price forecast is $8.16, which is an increase of 2,437.31% from the latest price.

Price Target
$8.16
(2,437.31% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Is BiomX (PHGE) Stock Up 8% Today?

BiomX (NYSEMKT: PHGE) stock is rising on Wednesday following the release of the company's earnings report for the fourth quarter of 2022. Starting off that earnings report is the company's net loss o...

1 day ago - InvestorPlace

BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (“CF”)

1 day ago - GlobeNewsWire

BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...

3 days ago - GlobeNewsWire

Why Is BiomX (PHGE) Stock Down 11% Today?

BiomX (NYSEMKT: PHGE) stock is taking a beating on Wednesday after the clinical-stage microbiome company revealed details of a new private placement. According to a news release, BiomX has entered in...

1 month ago - InvestorPlace

BiomX Announces $7.5 Million Private Placement

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered ...

1 month ago - GlobeNewsWire

BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage ther...

4 months ago - GlobeNewsWire

BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update

Continued Progress Enrolling Patients in Phase 1/2 Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis; Results from Part 1 of the Trial Now Expected in Q1 2023

5 months ago - GlobeNewsWire

BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022

NESS ZIONA, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage ther...

5 months ago - GlobeNewsWire

BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target...

7 months ago - Business Wire

BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...

8 months ago - Business Wire

BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...

8 months ago - Business Wire

BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that targe...

8 months ago - Business Wire

BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...

9 months ago - Business Wire

Why BiomX Shares Are Trading Higher Today?

BiomX Inc (NYSE: PHGE) has announced a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease (IBD).  BiomX is a clinical-stage microbiome company advancing ...

9 months ago - Benzinga

Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or “Company”) announces a new collaboration with Boehringer Ingelheim to identify biomarkers for inflam...

9 months ago - Business Wire

BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

BRANFORD, Conn. and NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage t...

9 months ago - Business Wire

BiomX Slashes Its Workforce By 50%, Atopic Dermatitis Program To Be Delayed

BiomX Inc (NYSE: PHGE) announced a corporate restructuring plan to focus its resources and extend the cash runway. The company had $55.7 million in cash, cash equivalents, short-term deposits, and a $...

11 months ago - Benzinga

BiomX Announces Corporate Restructuring

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...

11 months ago - Business Wire

BiomX Announces Publication in the Journal, Bioinformatics

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...

11 months ago - Business Wire

BiomX Reports First Quarter 2022 Financial Results and Provides Business Update

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...

11 months ago - Business Wire

BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...

11 months ago - Business Wire

BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...

11 months ago - Business Wire

BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...

1 year ago - Business Wire

BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target...

1 year ago - Business Wire